MedTrace Logo

Evaluation of Panel Reactive Antibody in Children Following Stage I Palliation for Hypoplastic Left Heart Syndrome

NCT01135485 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2017-08-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether children and adolescents 8-18 years of age with HLHS and related lesions who have undergone stage I palliation during infancy using an allograft patch demonstrate continued evidence of HLA antibody formation.

Conditions

  • Congenital Heart Disease

Sponsors & Collaborators

Principal Investigators

  • Robert E Shaddy, M.D. · Children's Hospital of Philadelphia

Eligibility

Min Age
8 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01135485 on ClinicalTrials.gov